Chronic heart failure in the United States: A manifestation of coronary artery disease

Circulation

Volumn 97, Issue 3, 1998, Pages 282-289

  Gheorghiade, Mihai ^a   Bonow, Robert O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Coronary disease; Endothelium; Heart failure; Ischemia

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PHOSPHODIESTERASE INHIBITOR;

CORONARY ARTERY DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0032570267     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.3.282     Document Type: Review

References (144)

1. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham Heart Study. N Engl J Med. 1990;322:1635-1641.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization races for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med. 1990;150:769-773.
3. National Center for Health Statistics. Detailed Diagnoses and Procedures, National Hospital Discharge Survey, 1990: Vital and Health Statistics, Series 13, No. 113. Hyattsville, Md: The Center; 1992. DHHS publication No. 92-1774.
4. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
5. Clinical Practice Guidelines. Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction. Rockville, Md: U.S. Dept of Health and Human Services. 1994:11-23, AHCPR publication No. 940612.
6. Williams JF Jr, Bristow MR, Fowler MB, Francis GR, Garson A, Gersh BJ, Hammer DF, Hiatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters WL. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995; 26:1376-1398.
7. Levit KR, Lazenby HC, Cown CA. National health expenditures, 1990. Health Care Fin Rev. 1991;13:29-54.
8. Graves EJ. National Hospital Discharge Survey: Annual Summary, 1993: Vital and Health Statistics, Series 13. National Health Survey. 1995;121: 1-63.
9. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:s107-s12.
10. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med. 1977;297:27-31, 254-258.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
12. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol. 1993;22(suppl A):119A-26A.
13. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-498.
14. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure, Criculation. 1996;94:2285-2296.
15. Bourassa MG, Gurné O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14A-19A.
16. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GR, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-1435.
18. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for the Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677-683.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
20. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Traistani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325: 303-310.
21. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zelpis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
22. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
23. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhes L, Gourley LA, Jolly MK, for the RADIANCE Study Group. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993;329:1-7.
24. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329: 149-155.
25. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri O, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77-82.
26. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
27. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, Demets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
29. Bart BA, Shaw LK, McCants CB, Fortin DF, Lee KL, O'Connor CM. The clinical and angiographic diagnosis of ischemic cardiomyopathy: a need to reassess our diagnostic criteria. Circulation. 1996;94(suppl I):I-338. Abstract.
30. Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, O'Connor CM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002-1008.
31. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
32. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342: 821-828.
33. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
34. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Cherey PI, on behalf of the ELITE Study Investigators. Randomised trial of Losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
35. Cody RJ, Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol. 1993;22(suppl A):165A-1671A.
36. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman B, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L, for the Vasodilator Heart Failure Trial (VHeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilatory therapy in patients with chronic heart failure treated with enalapril: VHeFT III. Circulation. 1997;96: 856-863.
37. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
38. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:38S-393.
39. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
40. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Oserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM, for the Second Prospective Randomised Study of Ibopamine on Mortality, and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997;349:971-977.
41. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky B, McNulty SE, Darius H, Schulman K, Zannad F, Thurmond HE, Harrell F, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) Am Heart J. 1997;134: 44-54.
42. Packer M, Rouleau J-L, Svedberg K, Pitt D, Fisher L, Klepper M, and the PROFILE Investigators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation. 1993; 88(suppl I): 1-301. Abstract.
43. Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil DL, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996; 348:7-12.
44. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of antiarrhythmic agent moricize on survival after myocardial infarction. N Engl J Med. 1992;327:227-233.
45. The Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223-231.
46. Simonton CA, Chatterjee K, Cody RJ, Kubo SH, Leonard D, Daly P, Rutman H. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol. 1985;6:453-459.
47. Haas GJ, Binkley PF, Carpenter JA, Leier CV. Central and regional hemodynamic effects of flosequinan for congestive heart failure. Am J Cardiol. 1989;63:1354-1359.
48. The German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and Xamoterol in chronic heart failure. Lancet. 1988;1:489-493.
49. Colucci WS, Sonnenblick EH, Adams KF, Berk M, Brozena SC, Cowley AJ, Grabicky JM, Kubo SA, Lejemtel T, Littler WA, Shabetai R, Shannon J, Starling MR, Touchon RC, Wasserman AG. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. J Am Coll Cardiol. 1993;22(suppl A):113A-118A.
50. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA, and the Principal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol. 1993;22:65-72.
51. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, Steingart RM, Levine TB, DeHaan H, for the FACET Investigators. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET). Circulation. 1993;88:492-501.
52. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Graybum PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
53. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silber MA, Gilbert EM, Johnson MR, GOSS FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated Cardiomyopathy. Lancet. 1993; 342:1441-1446.
54. Gilbert EM, Renlund DG, Olsen SL, Reynolds L, Mealey PC, Larrabee P, Bristow MR. Hemodynamic and neuroendocrine effects of chronic vesnannone administration in heart failure: a placebo-controlled trial. J Am Coll Cardiol. 1994;23:173A. Abstract.
55. Van Veldhuisen DJ, Man In't Veld AJ, Dunselman PHJM, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI, on behalf of the DIMT Study Group. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;22:1564-1573.
56. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wamica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pr.ivastatiii on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
57. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelrmen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt H, Færgeman O, Thorgeirsson G, Jönsson B, Schwartz JS, for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93: 1796-1802.
58. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995; 332:512-521.
59. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.
60. Frye RL. Clinical reality of lowering total and LDL cholesterol. Circulation. 1997;95:306-307.
61. Mancini GBJ, Henry GC, Macaya C, O'Neill BR, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luescher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
62. Daemen MJAP, Lombardi DM, Bosman FT, Schwatz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
63. Willich SN, Linderer T, Wegscheider K, Leizorovicz A, Alamercery I, Schröder R. Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior β-adrenergic blockade. Circulation. 1989; 80:853-858.
64. Packer M, Meiler J, Medina N, Yushak M, Gorlin R. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure: clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. Am J Cardiol. 1981; 48:939-945.
65. Schulz R, Guth BD, Pieper K, Martin C, Heusch G. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery: a model of short term hibernation. Circ Res. 1992; 70:1282-1295.
66. Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation. 1993;88:684-695.
67. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
68. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
69. Yusuf S, Pepine CJ, Garces C, Pouler H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
70. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
71. Rapaport E, Gheorghiade M. Pharmacologic therapies after myocardial infarction. Am J Med. 1996;101(suppl 4A):61S-70S.
72. Hirayama A, Adachi T, Asada S, Mishima M, Nanto S, Kusuoka H, Yamamoto K, Matsumura Y, Hori M, Inoue M, Kodama K. Late reperfusion for acute myocardial infarction limits the dilatation of left ventricle without the reduction of infarct size. Circulation. 1993;88:2565-1574.
73. Meijer A, Verheugt FWA, van Eenige MJ, Werter CJPJ. Left ventricular function at 3 months after successful thrombolysis: impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling. Circulation. 1994;90:1706-1714.
74. Lamas GA, Flaker GC, Mitchell G, Smith SC, Gersh BJ, Wun CC, Moyé L, Rouleau JL, Rutherford JD, Pfeffer MA, Braunwald E. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation. 1995;92:1101-1109.
75. Homans DC, Sublett E, Dai XZ, Bache RJ. Persistence of regional left ventricular dysfunction after exercise-induced myocardial ischemia. J Clin Invest. 1986;77:66-73.
76. Kloner RA, Allen J, Cox TA, Zheng Y, Ruiz CE. Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol. 1991;68:329-334.
77. Ambrosio G, Betocchi S, Pace L, Losi MA, Perrone-Filardi P, Soricelli A, Piscione F, Taube J, Squame F, Salvatore M, Weiss JL, Chiariello M. Prolonged impairment of regional contractile function after resolution of exercise-induced angina: evidence of myocardial stunning in patients with coronary artery disease. Circulation. 1996;94:2455-2464.
78. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146-1149.
79. Bolli R. Myocardial 'stunning' in man. Circulation. 1992;86:1671-1691.
80. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circuhtion. 1985;72(suppl V):V-123-V-135.
81. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for 'hibernating' myocardium. J Am Coll Cordiol. 1986;8:1467-1470.
82. Ross J Jr. Myocardial perfusion-contraction matching: implications for coronary artery disease and hibernation. Circulation. 1991;83:1076-1083.
83. Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol. 1995;75:17A-25A.
84. Rahimtoola SH. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol. 1995;75:16E-22E.
85. Schwarz ER, Schaper J, vom Dahl J, Altehoefer C, Grohmann B, Schoendube F, Sheehan FH, Vebis R, Buell U, Messmer BJ, Schafer W, Hanrath P. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol. 1996;27:1577-1585.
86. Elsässer A, Schlepper M, Klövekom WP, Cai W, Zimmermann R, Müller KD, Stresser R, Kostin S, Gagel C, Münkel B, Schaper W, Schaper J. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation. 1997;96:2920-2931.
87. Alderman EL, Fischer P, Litwin GC, Kaiser GC, Meyers WO, Maynard C, Levine F, Schloss M. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68:785-795.
88. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA. 1994;272:1528-1534.
89. Faulkner SL, Stoney WS, Alford WC. Ischemic cardiomyopathy: medical versus surgical treatment. J Thorac Cardiovasc Surg. 1977;74:77-82.
90. Pigott J, Kouchoukous N, Oberman A, Cutter GR. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol. 1985;5:1036-1045.
91. Bounous EP, Mark DB, Pollock BG, Hlatky MA, Harrell FE, Lee KL, Rankin JS, Wechsler AS, Pryor DB, Califf RM. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation. 1988;78(suppl I):I-151-I-157.
92. Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, Glower DD, Harrell FE, Lee KL, Califf RM, Sabiston DC. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease: 20 years of follow-up. Circulation. 1992;86(suppl II):II-198-II-104.
93. Elefteriades JA, Tous G Jr, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411-1417.
94. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation. 1993;87:1630-1641.
95. Bonow RO. Identification of viable myocardium. Circulation. 1996;94: 2674-2680.
96. Eitzman D, Al-Aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559-565.
97. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czemin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Schelbert HR, Phelps ME, Maddahi J. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994; 73: 527-533.
98. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, Maddahi J. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92:3436-3444.
99. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417-1423.
100. Paulus WJ, Vantrimpont PJ, Shah AM. Paracine coronary endothelial control of left ventricular function in humans. Circulation. 1995;92: 2119-2126.
101. Shen W, Hintze TH, Wolin MS. Nitric oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation. 1995;92:3505-3512.
102. Guarda E, Karwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
103. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation. 1995;92:3337-3349.
104. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation. 1996;93: 1214-1222.
105. Harrison DG, Freiman PC, Armstrong ML, Marcus ML, Heistad DD. Alterations of vascular reactivity in atherosclerosis. Circ Res. 1987;61(suppl II):II-74-II-80.
106. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
107. Dzau VJ, Gibbons GH, Cooke DP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. Circulation. 1993;87:705-719.
108. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide: complex physiology and complex molecular adaptations. Circulation. 1994;90:2556-2559.
109. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 1994;89(suppl 1):87-102.
110. Lüscher TF, Boulanger DM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension. 1992;19:117-130.
111. Levin ER. Endothelins. N Engl J Med. 1995;333:356-363.
112. 111a.Krüger D, Sheikhzadeh A, Giannitsis E, Stierle U. Cardiac release and kinetics of endothelin after severe short-lasting myocardial ischemia. J Am Coll Cardiol. 1997;30:942-946.
113. Treasure CB, Alexander RW. The dysfunctional endothelium in heart failure. J Am Coll Cardiol. 1993;22(suppl A):129A-134A.
114. Colucci WS. Myocardial endothelin: does it play a role in myocardial failure? Circulation. 1996;93:1069-1072.
115. Luskucoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
116. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496-1500.
117. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
118. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
119. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endotheliumdependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
120. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574.
121. Bonow RO, Vitale DF, Bacharach SL, Maron BJ, Green MV. Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects. J Am Coll Cardiol. 1988;11:50-58.
122. Wong WF, Gold S, Fukuyama O, Blanchette PL. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol. 1989;15: 1526-1528.
123. McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med. 1995;99:629-635.
124. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1992;325:1557-1564.
125. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med. 1992;117:502-510.
126. Aroesty JM, McKay RG, Heller GV, Royal HD, Als AV, Grossman W. Simultaneous assessment of left ventricular systolic and diastolic dysfunction during pacing induced ischemia. Circulation. 1985;71:889-900.
127. Carson P, Johnson G, Fletcher R, Cohn J, for the V-HeFT Cooperative Study Group. Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics, prognosis and response to therapy in the vasodilator in heart failure trials (V-HeFT). J Am Coll Cardiol. 1996;27:642-649.
128. McDermott MM, FeinglassJ, Lee PI, Metha S, Schmidt B, Lefevre F, Gheorghiade M. Systolic function, readmission rates, and survival among consecutively hospitalized congestive heart failure patients. Am Heart J. 1997;134:728-736.
129. McAlister FA, Teo KK, Taher M, Cheung L, Kiaii M, Yim R, Armstrong PW, Montague TJ, Humen DP. Comparison of treatment patterns and outcomes in heart failure patients with systolic versus diastolic left ventricular dysfunction. J Am Coll Cardiol. 1997;29:64A. Abstract.
130. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, KennedyJW, and the CASS Participants. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS Registry. J Am Coll Canliol. 1991;18:177-182.
131. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
132. Weber KT, Sun Y, Tyagi SC, Cleutjens JPM. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Canliol. 1994;26:279-292.
133. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504-2507.
134. Rutherford JD, Pfeffer MA, Moye, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. Circulation. 1994;90:1731-1738.
135. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
136. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
137. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JW, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307.
138. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621-1628.
139. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 1994;75:426-433.
140. Colucci WS. Apoptosis in the heart. N Engl J Med. 1996;335:1224-1226.
141. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141.
142. 140a.Chen C, Ma L, Linfert DR, Lie T, Fallon JT, Gillam LD, Waters DD, Tsongalis GJ. Myocardial cell death and apoptosis in hibernating myocardium. J Am Coll Cardiol. 1997;30:1407-1412.
143. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, Larosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Consensus Panel Statement: preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
144. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79:909-913.